Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is meaningful. It is not a verdict. It is an early clinical signal, and those are two very different animals.
A Small Dataset With Real Clinical Weight
The headline comes from 27 response-evaluable patients across 12 soft tissue sarcoma subtypes treated every two weeks. Eight had partial responses, producing the 30% response rate; five responses were confirmed and three remained unconfirmed at the cutoff. Disease control reached 85%, or 23 of 27 patients. All responses were ongoing, and 22 of 27 evaluable patients remained on treatment.
That is a striking collection of numbers in a disease family that is both rare and maddeningly heterogeneous. Soft tissue sarcoma encompasses more than 100 tumor subtypes. A drug that appears active across several of them could have genuine strategic value, because a narrowly useful therapy can still help patients, but a broader profile gives a development program much more room to breathe.
Still, nobody should get carried away over a 3.4-month median follow-up. The median duration of response has not been reached because the observation window is immature, not because durability has been settled. Early responses can fade. Unconfirmed responses may or may not hold up. Phase 1 oncology has embarrassed plenty of otherwise intelligent people who confused an exciting first snapshot with a finished picture.
The Dose Schedule Looks Like the Practical Win
What catches my attention as much as efficacy is the company’s move away from weekly dosing toward an every-two-week regimen. The first 18 patients received weekly ADCE-D01 at doses of 0.5 to 3.4 mg/kg. Based on pharmacokinetics, the next 29 received 3.4 to 5.5 mg/kg every two weeks. Management says activity trended better at higher doses, which is encouraging, though “trend” is doing a lot of work until more patients are enrolled.
The safety profile on the every-two-week schedule looks manageable on the information available. Low-grade nausea occurred in 59% of patients, infusion-related reactions in 41%, fatigue in 38%, and hair loss in 35%. Neutropenia occurred in 31%. Those are not trivial side effects, and cancer patients do not experience them as abstract percentages. But dose reductions occurred in only 10% of every-two-week patients, and no patient discontinued because of side effects in that group.
- Severe neutropenia was reported in 14% of patients receiving prophylactic G-CSF, versus 43% without it.
- The G-CSF group was receiving higher doses, making that comparison particularly notable, though the groups were very small.
- No interstitial lung disease, febrile neutropenia, or stomatitis was observed on the reported dataset.
- The maximum tolerated dose for the every-two-week regimen has not been reached.
Safety Will Determine How Much This Signal Is Worth
ADCE-D01 is an antibody-drug conjugate aimed at uPARAP, a receptor expressed in several cancers of mesenchymal origin. The scientific pitch is sensible: target a receptor with rapid internalization and differentiated tumor-versus-healthy-tissue expression, then deliver a deruxtecan payload. Sensible biology, however, is merely the price of admission in ADC development. The graveyard is full of elegant mechanisms that could not maintain a usable therapeutic window in real patients.
That is why the absence of discontinuations on the every-two-week regimen matters. It does not prove long-term tolerability, especially with only 29 patients on that schedule and evolving supportive care. It does suggest Adcendo may have found a dosing approach worth pursuing rather than simply pushing exposure until toxicity wrecks the program. For patients facing advanced disease, that distinction is not academic.
What a Careful Sector Watcher Should Follow
Adcendo is privately held, so this is not a ticker-driven event. The investor relevance sits in the broader ADC field and in whether a company can translate an early response signal into a credible registration path. The FDA has granted ADCE-D01 both Fast Track and Orphan Drug Designation for soft tissue sarcoma, useful tools but absolutely not approval stamps.
Encouraging Phase 1 efficacy gets attention; reproducible durability and manageable toxicity create a medicine.
The next updates need to answer plain, hard questions: Do the three unconfirmed responses become confirmed? How long do responses last as follow-up matures? Does activity remain visible across subtypes rather than being concentrated in a lucky pocket? And can higher doses preserve the current tolerability profile with G-CSF support?
For now, Adcendo has earned the right to keep enrolling ADCElerate1 in the United States and Europe. In a field with thin options and substantial unmet need, a 30% early response rate is worth respecting. It just is not time to declare victory before the clock has even started running.